The use of autologous stem-cell transplantation in the treatment of follicular lymphoma remains controversial ... from two randomized trials, GELF-86 and GELF-94. The inclusion of rituximab ...

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate of watch-and-wait patients was not inferior to that o ...

Follicular Lymphoma International Prognostic Index (FLIPI) and tumor burden, as judged by the GELF score, are each in use for risk stratification. A period of observation at diagnosis may be ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

New data from the Primary Rituximab And Maintenance study provide the strongest support for the use of rituximab maintenance in patients with follicular lymphoma. However, further considerations ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a chemotherapy-free regimen with Roche’s MabThera. The cost-effectiveness agency ...

"China conditionally approves Hutchmed’s Tazverik for follicular lymphoma" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this ...